// App-Quantinova.ai

5065 : Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC) A physician survey linked to patient chart reviews in the United States.

Researchers

Presenter

  • Stephen J. Freedland

Principal Investigators

  • Zachary William Abraham Klaassen

  • Neeraj Agarwal

  • Rickard Sandin

  • Andrea Leith

  • Amanda Ribbands

  • Emily Clayton

  • Jake Butcher

  • Liane Gillespie-Akar

  • Dave Russell

  • Agnes Hong

  • Krishnan Ramaswamy

  • Daniel J. George

Medical Centers

  • Division of Urology, Department of Surgery, Cedars-Sinai Medical Center and Department of Surgery, Durham Veterans Affairs Health Care System, Durham, NC

  • Division of Urology, Medical College of Georgia at Augusta University, Georgia Cancer Center, Augusta, GA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Pfizer AB, Sollentuna, Sweden

  • Adelphi Real World, Bollington, United Kingdom

  • Pfizer Inc, New York, NY

  • Astellas Pharma, Inc., Northbrook, IL

  • Duke Cancer Institute, Durham, NC

Locations

  • United States

  • Sweden

  • United Kingdom

Companies

  • PharmAbcine Inc.

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved